miR-34a was reported to target PD-L1 in various cancer cells including cells of osteosarcoma, acute myeloid leukemia, and lung, breast, and colon cancer (Cortez et al., 2015; Wang et al., 2015). This evidence concerns the gene CD274 and cancer.